Abstract 457P
Background
Vitamin D deficiency is associated with various kinds of cancer. Moreover, vitamin D level possibly has an inverse relationship with cancer mortality. The data on vitamin D status among Thai cancer patients and its association with cancer survival are scarce. Objectives: The primary outcome was to determine the prevalence of vitamin D deficiency among unselected Thai cancer patients. The secondary outcomes were to explore the effect of cancer treatment upon vitamin D status, the independent predictive factor(s) of vitamin D deficiency among cancer patients and its potential independent factor of cancer survival.
Methods
There were 106 consecutive cancer patients participated in this prospective descriptive study conducted at Division of Medical Oncology. Vitamin D (25(OH) D) levels were collected before and after cancer treatment. Demographic data, vitamin D status, and treatment outcomes were collected and analysed.
Results
There were 106 consecutive cancer patients participated in this study. Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators found that almost all of the cancer patients had vitamin D deficiency (102 of 106, 96.2%). Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators did not demonstrate the significant change of vitamin D level (mean change = -1.46 (95% C.I., -3.33-0.41), p = 0.124) when the blood samples were collected before and after cancer treatment. Therefore, cancer treatment was unlikely to affect the vitamin D status. There was a trend towards inverse relationship between the BMI and vitamin D level. At the median follow-up time of 254.5 days (IQR 220-297), the investigators revealed that low BSA (BSA < 1.5 m2), PS 2 at presentation was the independent predictive factors of survival, according to the multi-variate analysis.
Conclusions
Nearly all Thai cancer patients have vitamin D deficiency. Cancer treatment does not affect the vitamin D status. Low serum vitamin D level does not affect survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chavapon Ngokngarm/Vajira hospital, Thailand.
Funding
Medical Research Fund of Faculty Medicine Vajira Hospital, Navamindradhiraj University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract